Literature DB >> 28866674

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.

Allan J Collins1, Bertram Pitt, Nancy Reaven, Susan Funk, Karen McGaughey, Daniel Wilson, David A Bushinsky.   

Abstract

BACKGROUND: The relationship between serum potassium, mortality, and conditions commonly associated with dyskalemias, such as heart failure (HF), chronic kidney disease (CKD), and/or diabetes mellitus (DM) is largely unknown.
METHODS: We reviewed electronic medical record data from a geographically diverse population (n = 911,698) receiving medical care, determined the distribution of serum potassium, and the relationship between an index potassium value and mortality over an 18-month period in those with and without HF, CKD, and/or DM. We examined the association between all-cause mortality and potassium using a cubic spline regression analysis in the total population, a control group, and in HF, CKD, DM, and a combined cohort.
RESULTS: 27.6% had a potassium <4.0 mEq/L, and 5.7% had a value ≥5.0 mEq/L. A U-shaped association was noted between serum potassium and mortality in all groups, with lowest all-cause mortality in controls with potassium values between 4.0 and <5.0 mEq/L. All-cause mortality rates per index potassium between 2.5 and 8.0 mEq/L were consistently greater with HF 22%, CKD 16.6%, and DM 6.6% vs. controls 1.2%, and highest in the combined cohort 29.7%. Higher mortality rates were noted in those aged ≥65 vs. 50-64 years. In an adjusted model, all-cause mortality was significantly elevated for every 0.1 mEq/L change in potassium <4.0 mEq/L and ≥5.0 mEq/L. Diuretics and renin-angiotensin-aldosterone system inhibitors were related to hypokalemia and hyperkalemia respectively.
CONCLUSION: Mortality risk progressively increased with dyskalemia and was differentially greater in those with HF, CKD, or DM.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; Diabetes; Heart failure; Hyperkalemia; Hypokalemia; Mortality

Mesh:

Substances:

Year:  2017        PMID: 28866674      PMCID: PMC5637309          DOI: 10.1159/000479802

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  23 in total

Review 1.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

2.  Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study.

Authors:  Bouwe P Krijthe; Jan Heeringa; Jan A Kors; Albert Hofman; Oscar H Franco; Jacqueline C M Witteman; Bruno H Stricker
Journal:  Int J Cardiol       Date:  2013-08-24       Impact factor: 4.164

3.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.

Authors:  Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge
Journal:  Eur Heart J       Date:  2006-05-18       Impact factor: 29.983

4.  Sodium zirconium cyclosilicate in hyperkalemia.

Authors:  David K Packham; Henrik S Rasmussen; Philip T Lavin; Mohamed A El-Shahawy; Simon D Roger; Geoffrey Block; Wajeh Qunibi; Pablo Pergola; Bhupinder Singh
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

5.  An electronic alert to decrease Kayexalate ordering.

Authors:  David E Leaf; Xingxing S Cheng; Jason L Sanders; Mallika Mendu; Gordon D Schiff; David B Mount; Hasan Bazari
Journal:  Ren Fail       Date:  2016-05-17       Impact factor: 2.606

Review 6.  Advances in treatment of hyperkalemia in chronic kidney disease.

Authors:  Pantelis A Sarafidis; Panagiotis I Georgianos; George L Bakris
Journal:  Expert Opin Pharmacother       Date:  2015-09-02       Impact factor: 3.889

7.  Serum and dialysate potassium concentrations and survival in hemodialysis patients.

Authors:  Csaba P Kovesdy; Deborah L Regidor; Rajnish Mehrotra; Jennie Jing; Charles J McAllister; Sander Greenland; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

8.  Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.

Authors:  C Barrett Bowling; Bertram Pitt; Mustafa I Ahmed; Inmaculada B Aban; Paul W Sanders; Marjan Mujib; Ruth C Campbell; Thomas E Love; Wilbert S Aronow; Richard M Allman; George L Bakris; Ali Ahmed
Journal:  Circ Heart Fail       Date:  2010-01-26       Impact factor: 8.790

Review 9.  Diuretic-related side effects: development and treatment.

Authors:  Doemnic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-09       Impact factor: 3.738

10.  Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease.

Authors:  Hsiao-Han Wang; Chi-Chih Hung; Daw-Yang Hwang; Mei-Chuan Kuo; Yi-Wen Chiu; Jer-Ming Chang; Jer-Chia Tsai; Shang-Jyh Hwang; Julian L Seifter; Hung-Chun Chen
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  89 in total

Review 1.  Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.

Authors:  Javed Butler; Shilpa Vijayakumar; Bertram Pitt
Journal:  Eur J Heart Fail       Date:  2018-06-08       Impact factor: 15.534

Review 2.  Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Authors:  Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney
Journal:  Curr Diab Rep       Date:  2019-01-23       Impact factor: 4.810

Review 3.  Acute Management of Hyperkalemia.

Authors:  Mengyang Liu; Zubaid Rafique
Journal:  Curr Heart Fail Rep       Date:  2019-06

Review 4.  Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.

Authors:  Redi Llubani; Davor Vukadinović; Christian Werner; Nikolaus Marx; Stephen Zewinger; Michael Böhm
Journal:  Curr Heart Fail Rep       Date:  2018-12

5.  Prevalence and correlates of hyperkalemia in a renal nutrition clinic.

Authors:  Claudia D'Alessandro; Andrea Cumetti; Erica Pardini; Claudia Mannucci; Piera Serio; Riccardo Morganti; Adamasco Cupisti
Journal:  Intern Emerg Med       Date:  2020-05-07       Impact factor: 3.397

6.  Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study.

Authors:  Vincenzo Panuccio; Daniela Leonardis; Rocco Tripepi; Maria Carmela Versace; Claudia Torino; Giovanni Tripepi; Graziella D'Arrigo; Francesca Mallamaci; Carmine Zoccali
Journal:  Intern Emerg Med       Date:  2021-02-11       Impact factor: 3.397

Review 7.  Regulation of muscle potassium: exercise performance, fatigue and health implications.

Authors:  Michael I Lindinger; Simeon P Cairns
Journal:  Eur J Appl Physiol       Date:  2021-01-04       Impact factor: 3.078

Review 8.  Intracellular chloride: a regulator of transepithelial transport in the distal nephron.

Authors:  Aylin R Rodan
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

9.  Predictors of Hyperkalemia and Hypokalemia in Individuals with Diabetes: a Classification and Regression Tree Analysis.

Authors:  Emily B Schroeder; John L Adams; Michel Chonchol; Gregory A Nichols; Patrick J O'Connor; J David Powers; Julie A Schmittdiel; Susan M Shetterly; John F Steiner
Journal:  J Gen Intern Med       Date:  2020-04-16       Impact factor: 5.128

10.  Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Christina Nowack; Peter Kolkhof; Anna C Ferreira; Patrick Schloemer; Gerasimos Filippatos
Journal:  Am J Nephrol       Date:  2019-10-25       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.